Panbela presents clinical data on phase 1b clinical trial of sbp-101 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pda at 2022 asco gi meeting

Minneapolis, jan. 24, 2022 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced the presentation of interim clinical data from its phase 1b combination therapy study of sbp-101, a proprietary polyamine analogue, with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (pda), at the american society of clinical oncology (asco) gastrointestinal (gi) meeting that took place january 20-22, 2022.
PBLA Ratings Summary
PBLA Quant Ranking